Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jun;80(8):1190–1196. doi: 10.1038/sj.bjc.6990485

BIRICODAR (VX-710; Incel™): an effective chemosensitizer in neuroblastoma

T Yanagisawa 1, A Newman 1, H Coley 2, J Renshaw 1, C R Pinkerton 1, K Pritchard-Jones 1
PMCID: PMC2362368  PMID: 10376971

Abstract

Clinical studies have suggested that both MDR1 and MRP may play a significant role in the chemosensitivity and outcome of neuroblastoma. To clarify the nature of multidrug resistance (MDR) in this tumour a series of six neuroblastoma cell lines have been characterized with regard to P-glycoprotein, MRP and LRP expression using immunocytochemistry and expression of MDR1, MRP, LRP and topoisomerase II genes using reverse transcription polymerase chain reaction (RT-PCR). By RT-PCR, all lines expressed MRP, five expressed LRP and four expressed MDR1, but protein levels of each of these were variable. Chemosensitization to a range of MDR-associated drugs (vincristine, doxorubicin, etoposide, taxotere, topotecan) and non-MDR-associated drugs (cisplatin, melphalan) by three modulating agents, cyclosporin A, PSC 833 and the novel Biricodar (VX-710; Incel™), was evaluated using a colourimetric cytotoxicity assay (MTS). Alteration of daunorubicin efflux by these agents was evaluated using FACS analysis. Clonogenic assay was used to study the influence of these chemosensitizers on vincristine cytotoxicity. Marked sensitization to vincristine was observed in MDR1-positive lines, and a similar but less consistent effect was seen with taxotere, doxorubicin and etoposide. With MRP-positive, MDR-negative lines, only VX-710 caused consistent sensitization. These data confirm MDR1 and MRP expression as contributory factors in chemoresistance in neuroblastoma and indicate that VX-710 may be a useful modulator of both mechanisms and worthy of clinical evaluation in this tumour. © 1999 Cancer Research Campaign

Full Text

The Full Text of this article is available as a PDF (187.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beck J., Handgretinger R., Dopfer R., Klingebiel T., Niethammer D., Gekeler V. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol. 1995 Feb;89(2):356–363. doi: 10.1111/j.1365-2141.1995.tb03312.x. [DOI] [PubMed] [Google Scholar]
  2. Beck W. T., Grogan T. M., Willman C. L., Cordon-Cardo C., Parham D. M., Kuttesch J. F., Andreeff M., Bates S. E., Berard C. W., Boyett J. M. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res. 1996 Jul 1;56(13):3010–3020. [PubMed] [Google Scholar]
  3. Beketic-Oreskovic L., Durán G. E., Chen G., Dumontet C., Sikic B. I. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst. 1995 Nov 1;87(21):1593–1602. doi: 10.1093/jnci/87.21.1593. [DOI] [PubMed] [Google Scholar]
  4. Biedler J. L., Helson L., Spengler B. A. Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res. 1973 Nov;33(11):2643–2652. [PubMed] [Google Scholar]
  5. Biedler J. L., Spengler B. A. Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science. 1976 Jan 16;191(4223):185–187. doi: 10.1126/science.942798. [DOI] [PubMed] [Google Scholar]
  6. Boote D. J., Dennis I. F., Twentyman P. R., Osborne R. J., Laburte C., Hensel S., Smyth J. F., Brampton M. H., Bleehen N. M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996 Feb;14(2):610–618. doi: 10.1200/JCO.1996.14.2.610. [DOI] [PubMed] [Google Scholar]
  7. Bordow S. B., Haber M., Madafiglio J., Cheung B., Marshall G. M., Norris M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 1994 Oct 1;54(19):5036–5040. [PubMed] [Google Scholar]
  8. Bourhis J., Bénard J., Hartmann O., Boccon-Gibod L., Lemerle J., Riou G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst. 1989 Sep 20;81(18):1401–1405. doi: 10.1093/jnci/81.18.1401. [DOI] [PubMed] [Google Scholar]
  9. Cairo M. S., Siegel S., Anas N., Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res. 1989 Feb 15;49(4):1063–1066. [PubMed] [Google Scholar]
  10. Chan H. S., DeBoer G., Haddad G., Gallie B. L., Ling V. Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am. 1995 Apr;9(2):275–318. [PubMed] [Google Scholar]
  11. Chan H. S., Haddad G., Thorner P. S., DeBoer G., Lin Y. P., Ondrusek N., Yeger H., Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med. 1991 Dec 5;325(23):1608–1614. doi: 10.1056/NEJM199112053252304. [DOI] [PubMed] [Google Scholar]
  12. Cowie F. J., Pinkerton C. R., Phillips M., Dick G., Judson I., McCarthy P. T., Flanagan R. J. Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer. 1995 Apr;71(4):877–881. doi: 10.1038/bjc.1995.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cowie F., Pinkerton C. R. Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance. J Clin Oncol. 1994 Sep;12(9):1998–1999. doi: 10.1200/JCO.1994.12.9.1998. [DOI] [PubMed] [Google Scholar]
  14. Feller N., Kuiper C. M., Lankelma J., Ruhdal J. K., Scheper R. J., Pinedo H. M., Broxterman H. J. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer. 1995 Sep;72(3):543–549. doi: 10.1038/bjc.1995.371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Futscher B. W., Blake L. L., Gerlach J. H., Grogan T. M., Dalton W. S. Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Anal Biochem. 1993 Sep;213(2):414–421. doi: 10.1006/abio.1993.1440. [DOI] [PubMed] [Google Scholar]
  16. Germann U. A., Ford P. J., Shlyakhter D., Mason V. S., Harding M. W. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs. 1997 Feb;8(2):141–155. doi: 10.1097/00001813-199702000-00005. [DOI] [PubMed] [Google Scholar]
  17. Germann U. A., Shlyakhter D., Mason V. S., Zelle R. E., Duffy J. P., Galullo V., Armistead D. M., Saunders J. O., Boger J., Harding M. W. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anticancer Drugs. 1997 Feb;8(2):125–140. doi: 10.1097/00001813-199702000-00004. [DOI] [PubMed] [Google Scholar]
  18. Goodwin C. J., Holt S. J., Downes S., Marshall N. J. Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS. J Immunol Methods. 1995 Feb 13;179(1):95–103. doi: 10.1016/0022-1759(94)00277-4. [DOI] [PubMed] [Google Scholar]
  19. Hills C. A., Kelland L. R., Abel G., Siracky J., Wilson A. P., Harrap K. R. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer. 1989 Apr;59(4):527–534. doi: 10.1038/bjc.1989.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lum B. L., Fisher G. A., Brophy N. A., Yahanda A. M., Adler K. M., Kaubisch S., Halsey J., Sikic B. I. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer. 1993 Dec 1;72(11 Suppl):3502–3514. doi: 10.1002/1097-0142(19931201)72:11+<3502::aid-cncr2820721618>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  21. Norris M. D., Bordow S. B., Marshall G. M., Haber P. S., Cohn S. L., Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med. 1996 Jan 25;334(4):231–238. doi: 10.1056/NEJM199601253340405. [DOI] [PubMed] [Google Scholar]
  22. Pike B. L., Robinson W. A. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970 Aug;76(1):77–84. doi: 10.1002/jcp.1040760111. [DOI] [PubMed] [Google Scholar]
  23. Rowinsky E. K., Smith L., Wang Y. M., Chaturvedi P., Villalona M., Campbell E., Aylesworth C., Eckhardt S. G., Hammond L., Kraynak M. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol. 1998 Sep;16(9):2964–2976. doi: 10.1200/JCO.1998.16.9.2964. [DOI] [PubMed] [Google Scholar]
  24. Stein U., Walther W., Laurencot C. M., Scheffer G. L., Scheper R. J., Shoemaker R. H. Tumor necrosis factor-alpha and expression of the multidrug resistance-associated genes LRP and MRP. J Natl Cancer Inst. 1997 Jun 4;89(11):807–813. doi: 10.1093/jnci/89.11.807. [DOI] [PubMed] [Google Scholar]
  25. Tumilowicz J. J., Nichols W. W., Cholon J. J., Greene A. E. Definition of a continuous human cell line derived from neuroblastoma. Cancer Res. 1970 Aug;30(8):2110–2118. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES